Vertex Pharmaceuticals (VRTX) closed at $558.88 on October 30, 2026, up 3.5% from the previous close, on volume of 2,529,809 shares (30-day average 1,204,955).
Data as of October 30, 2026.
30-Oct-2026
Vertex Pharmaceuticals Q3 2026 Earnings Preview
Seeking Alpha News (Sun, 1-Nov 5:35 PM ET)
The Week That Was, The Week Ahead: Macro and Markets, November 1
TipRanks (Sun, 1-Nov 4:50 AM ET)
Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growth
Seeking Alpha News (Sat, 31-Oct 10:40 AM ET)
Catalyst watch: Election drama, jobs report, Apple and McDonald's in the earnings confessional
Seeking Alpha News (Fri, 30-Oct 3:00 PM ET)
Vertex Advances New ADPKD Candidate With Fresh Phase 1 Study Update
TipRanks (Fri, 30-Oct 12:31 PM ET)
TipRanks (Wed, 28-Oct 2:50 AM ET)
Business Wire (Fri, 23-Oct 1:42 PM ET)
Vertex Appoints Daniel Brennan to its Board of Directors
Business Wire (Tue, 20-Oct 4:05 PM ET)
Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis Conference
Business Wire (Fri, 9-Oct 1:15 PM ET)
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
Business Wire (Wed, 7-Oct 4:00 PM ET)
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
Vertex Pharmaceuticals trades on the NASDAQ stock market under the symbol VRTX.
As of October 30, 2026, VRTX stock price climbed to $558.88 with 2,529,809 million shares trading.
VRTX has a beta of 0.39, meaning it tends to be less sensitive to market movements. VRTX has a correlation of 0.03 to the broad based SPY ETF.
VRTX has a market cap of $141.65 billion. This is considered a Large Cap stock.
Last quarter Vertex Pharmaceuticals reported $3 billion in Revenue and $4.73 earnings per share. This beat revenue expectation by $120 million and exceeded earnings estimates by $.10.
In the last 3 years, VRTX traded as high as $563.80 and as low as $341.90.
The top ETF exchange traded funds that VRTX belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.
VRTX has outperformed the market in the last year with a price return of +33.1% while the SPY ETF gained +12.3%. VRTX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +16.0% and +11.8%, respectively, while the SPY returned +2.1% and -1.0%, respectively.
VRTX support price is $529.67 and resistance is $550.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRTX shares will trade within this expected range on the day.
